AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Omega Fund VIII, was oversubscribed and beat its $600 million target, reaching the hard cap. With Fund VIII, the firm will continue to execute its strategy of creating and investing in life sciences ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will increase.

Commerce Secretary Howard Lutnick said Trump's new tariff policies are focused on ending the U.S.'s reliance on foreign supply of key pharmaceutical products. "We are proud that AstraZeneca has made ...